ArticleCase reports in gastroenterology
Adebrelimab Combined with Chemotherapy for Esophageal Neuroendocrine Carcinoma: A Case Report.
Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Esophageal neuroendocrine carcinoma is an extremely rare type of esophageal cancer. Due to the limited number of cases, there are no established diagnostic and treatment guidelines. Case Presentation: A 60-year-old male presented with dysphagia and was subsequently diagnosed with large cell neuroendocrine carcinoma of the esophagus. He received four cycles of treatment with adebrelimab combined with etoposide and carboplatin, which resulted in significant tumor shrinkage. Conclusion: Esophageal neuroendocrine carcinoma is a highly malignant tumor with a high mortality rate. A better understanding of its diagnosis and treatment strategies may contribute to favorable trends in patient outcomes, while its actual effect on long-term prognosis remains to be validated with extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.